Get App
Download App Scanner
Scan to Download
Advertisement
This Article is From Nov 07, 2024

Lupin Q2 Results: Profit Beats Estimates, Revenue Up 13%

Lupin's operating profit or Ebitda climbed 42% to Rs 1,308 crore during the September quarter.

Lupin Q2 Results: Profit Beats Estimates, Revenue Up 13%
Lupin Ltd.'s Q2 results show a 74% rise in net profit and a 13% increase in revenue, driven by a significant improvement in margins and strong operational performance, surpassing market estimates. (Photo source: company website)

Lupin Ltd.'s consolidated net profit rose 74% in the second quarter of the financial year, beating analysts' estimates.

The company posted a net profit of Rs 852.6 crore in the quarter ended September in comparison to Rs 489.7 crore in the year-ago period, according to an exchange filing on Thursday. Analysts tracked by Bloomberg had estimated a profit of Rs 742 crore.

Lupin Q2 FY25 Earnings Highlights (Consolidated, YoY)

  • Revenue up 13% to Rs 5,672.7 crore versus Rs 5,038.6 crore (Bloomberg estimate: Rs 5,560 crore).

    Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay

  • Ebitda up 41.7% to Rs 1,308 crore versus Rs 923 crore (Bloomberg estimates Rs 1,203 crore).

  • Margin expands to 23.1% versus 18.3% (Estimate: 21.6%).

  • Net profit up 74% to Rs 852.6 crore versus Rs 489.7 crore (Estimate: Rs 742 crore).

North America

Lupin's North America sales reached Rs 1,971 crore, a 5.6% increase and accounting for 36% of the company's global sales. US sales rose to Rs 1,834 crore from Rs 1,776 crore in the year-ago period.

Lupin received 10 abbreviated-new-drug-application approvals from the FDA and launched two new products, bringing its US generics portfolio to 162 products.

India

Lupin's India formulation sales reached Rs 2,010 crore, marking an 19% increase and representing 37% of Lupin's global sales. During the first half of the fiscal, the company launched five brands across diabetes, neuro/CNS, gastrointestinal, cardiac and gynae therapies.

Sales in growth markets (Asia–Pacific and Latin America) reached Rs 490 crore, a 12% increase and contributing 9% to Lupin's global sales. Sales in Europe, the Middle East and Africa rose 20% to Rs 569 crore, accounting for 10% of the company's global sales.

Global active-pharmaceutical-ingredient sales rose 9.7% to Rs 294 crore, contributing 5% to the company's global sales.

Shares of Lupin closed 2.52% lower at Rs 2,110.55 apiece on the NSE, compared to a 1.16% decline in the benchmark Nifty 50.

Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search
Add NDTV Profit As Google Preferred Source
Listen to the latest songs, only on JioSaavn.com